| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 46 | 2025 | 961 | 12.660 |
Why?
|
| Pre-Exposure Prophylaxis | 19 | 2025 | 186 | 8.010 |
Why?
|
| Anti-HIV Agents | 19 | 2025 | 195 | 6.450 |
Why?
|
| Emergency Service, Hospital | 10 | 2024 | 579 | 2.550 |
Why?
|
| Electronic Health Records | 7 | 2024 | 372 | 2.400 |
Why?
|
| Sexual and Gender Minorities | 7 | 2024 | 250 | 2.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 557 | 1.730 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 333 | 1.450 |
Why?
|
| Health Personnel | 4 | 2025 | 234 | 1.440 |
Why?
|
| Chicago | 16 | 2024 | 1464 | 1.360 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2024 | 292 | 1.350 |
Why?
|
| Betacoronavirus | 4 | 2020 | 283 | 1.270 |
Why?
|
| Medical Informatics | 2 | 2021 | 48 | 1.220 |
Why?
|
| Clostridium Infections | 2 | 2023 | 128 | 1.220 |
Why?
|
| Homosexuality, Male | 8 | 2023 | 332 | 1.200 |
Why?
|
| Humans | 79 | 2025 | 93522 | 1.190 |
Why?
|
| Ambulatory Care Facilities | 5 | 2023 | 117 | 1.170 |
Why?
|
| Telemedicine | 2 | 2022 | 225 | 1.150 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 57 | 1.150 |
Why?
|
| Adult | 39 | 2025 | 27921 | 1.130 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 338 | 1.120 |
Why?
|
| Female | 47 | 2025 | 48708 | 1.050 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 109 | 0.990 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 57 | 0.910 |
Why?
|
| Middle Aged | 33 | 2025 | 27580 | 0.900 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 43 | 0.890 |
Why?
|
| Pandemics | 11 | 2022 | 873 | 0.890 |
Why?
|
| Academic Medical Centers | 3 | 2025 | 394 | 0.880 |
Why?
|
| AIDS Serodiagnosis | 3 | 2022 | 27 | 0.830 |
Why?
|
| Algorithms | 5 | 2024 | 1954 | 0.820 |
Why?
|
| Male | 39 | 2025 | 44564 | 0.810 |
Why?
|
| Contact Tracing | 2 | 2021 | 29 | 0.810 |
Why?
|
| Natural Language Processing | 2 | 2021 | 41 | 0.800 |
Why?
|
| Risk Assessment | 3 | 2020 | 2441 | 0.790 |
Why?
|
| Sexual Partners | 3 | 2024 | 106 | 0.790 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 67 | 0.760 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 37 | 0.750 |
Why?
|
| Influenza, Human | 2 | 2016 | 347 | 0.750 |
Why?
|
| Antimicrobial Stewardship | 2 | 2021 | 24 | 0.710 |
Why?
|
| Hepatitis C | 1 | 2023 | 182 | 0.680 |
Why?
|
| United States | 13 | 2024 | 7622 | 0.660 |
Why?
|
| Hospitalization | 5 | 2022 | 937 | 0.650 |
Why?
|
| Virus Shedding | 1 | 2020 | 19 | 0.650 |
Why?
|
| Viral Load | 4 | 2024 | 154 | 0.640 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 9 | 0.640 |
Why?
|
| Ambulatory Care | 2 | 2023 | 193 | 0.630 |
Why?
|
| Retrospective Studies | 20 | 2024 | 10166 | 0.630 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 122 | 0.620 |
Why?
|
| Continuity of Patient Care | 4 | 2024 | 176 | 0.620 |
Why?
|
| Respiratory System | 1 | 2020 | 117 | 0.610 |
Why?
|
| Qualitative Research | 4 | 2024 | 347 | 0.600 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.600 |
Why?
|
| Patient Compliance | 1 | 2021 | 237 | 0.590 |
Why?
|
| HIV-1 | 1 | 2020 | 173 | 0.590 |
Why?
|
| RNA, Viral | 1 | 2020 | 285 | 0.590 |
Why?
|
| Infection Control | 1 | 2020 | 130 | 0.590 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 13 | 0.570 |
Why?
|
| Heterosexuality | 1 | 2018 | 20 | 0.560 |
Why?
|
| Travel | 1 | 2018 | 73 | 0.540 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 85 | 0.540 |
Why?
|
| Antifungal Agents | 3 | 2017 | 122 | 0.530 |
Why?
|
| Cross Infection | 2 | 2016 | 155 | 0.520 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 836 | 0.520 |
Why?
|
| Referral and Consultation | 1 | 2020 | 375 | 0.520 |
Why?
|
| Coinfection | 4 | 2021 | 67 | 0.520 |
Why?
|
| Itraconazole | 1 | 2016 | 12 | 0.500 |
Why?
|
| Violence | 1 | 2018 | 152 | 0.500 |
Why?
|
| Residence Characteristics | 1 | 2018 | 212 | 0.490 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 38 | 0.480 |
Why?
|
| Sorbitol | 1 | 2016 | 9 | 0.480 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 9 | 0.480 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 66 | 0.480 |
Why?
|
| Focus Groups | 3 | 2025 | 184 | 0.460 |
Why?
|
| Population Surveillance | 1 | 2016 | 213 | 0.460 |
Why?
|
| Automation | 1 | 2016 | 105 | 0.460 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 150 | 0.450 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 149 | 0.430 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 22 | 0.430 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 37 | 0.430 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 52 | 0.420 |
Why?
|
| Hospitals | 1 | 2016 | 329 | 0.410 |
Why?
|
| Young Adult | 11 | 2025 | 6930 | 0.400 |
Why?
|
| Machine Learning | 3 | 2022 | 341 | 0.400 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 168 | 0.400 |
Why?
|
| Logistic Models | 3 | 2022 | 1243 | 0.380 |
Why?
|
| Candida | 3 | 2017 | 20 | 0.370 |
Why?
|
| Candidiasis | 3 | 2017 | 39 | 0.370 |
Why?
|
| Mass Screening | 5 | 2024 | 696 | 0.350 |
Why?
|
| Risk Factors | 6 | 2023 | 5901 | 0.350 |
Why?
|
| Time Factors | 5 | 2022 | 5412 | 0.350 |
Why?
|
| Sepsis | 1 | 2016 | 388 | 0.350 |
Why?
|
| Comorbidity | 4 | 2023 | 1007 | 0.350 |
Why?
|
| Electronics | 2 | 2021 | 19 | 0.340 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 286 | 0.330 |
Why?
|
| Cities | 2 | 2021 | 57 | 0.320 |
Why?
|
| Soft Tissue Infections | 2 | 2021 | 27 | 0.320 |
Why?
|
| Vaccination | 2 | 2022 | 304 | 0.320 |
Why?
|
| Syphilis | 2 | 2021 | 35 | 0.300 |
Why?
|
| Adolescent | 10 | 2025 | 9607 | 0.300 |
Why?
|
| Inpatients | 3 | 2021 | 345 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 146 | 0.280 |
Why?
|
| Models, Theoretical | 2 | 2021 | 494 | 0.270 |
Why?
|
| Family Planning Services | 2 | 2025 | 47 | 0.270 |
Why?
|
| Aged | 14 | 2021 | 20439 | 0.260 |
Why?
|
| Urban Population | 2 | 2018 | 234 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2024 | 917 | 0.250 |
Why?
|
| Survival Analysis | 2 | 2022 | 1524 | 0.230 |
Why?
|
| Medicare | 2 | 2020 | 455 | 0.230 |
Why?
|
| Epidemics | 1 | 2025 | 41 | 0.220 |
Why?
|
| Community-Acquired Infections | 2 | 2021 | 65 | 0.210 |
Why?
|
| Patient Portals | 1 | 2024 | 21 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 73 | 0.190 |
Why?
|
| Age Factors | 2 | 2018 | 1906 | 0.190 |
Why?
|
| Program Evaluation | 1 | 2024 | 315 | 0.190 |
Why?
|
| Social Support | 1 | 2024 | 233 | 0.190 |
Why?
|
| Safe Sex | 2 | 2020 | 24 | 0.180 |
Why?
|
| Social Media | 1 | 2024 | 111 | 0.180 |
Why?
|
| Prospective Studies | 2 | 2021 | 4562 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2024 | 756 | 0.180 |
Why?
|
| Anxiety | 1 | 2024 | 337 | 0.180 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2021 | 25 | 0.170 |
Why?
|
| HIV | 1 | 2021 | 47 | 0.170 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 64 | 0.170 |
Why?
|
| Minority Groups | 1 | 2022 | 149 | 0.170 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 15 | 0.170 |
Why?
|
| Demography | 1 | 2021 | 189 | 0.170 |
Why?
|
| Needle Sharing | 1 | 2020 | 15 | 0.160 |
Why?
|
| Risk Management | 1 | 2020 | 38 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 12 | 0.160 |
Why?
|
| Azithromycin | 1 | 2020 | 16 | 0.160 |
Why?
|
| Drug Resistance, Multiple, Fungal | 2 | 2017 | 3 | 0.160 |
Why?
|
| Cephalosporins | 1 | 2020 | 25 | 0.160 |
Why?
|
| Postal Service | 1 | 2020 | 23 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 41 | 0.160 |
Why?
|
| Social Networking | 1 | 2021 | 85 | 0.160 |
Why?
|
| Depression | 1 | 2024 | 544 | 0.160 |
Why?
|
| Critical Illness | 1 | 2023 | 343 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 624 | 0.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1847 | 0.150 |
Why?
|
| Bias | 1 | 2020 | 137 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 660 | 0.150 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 9 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 481 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 920 | 0.150 |
Why?
|
| Condoms | 1 | 2019 | 38 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 283 | 0.140 |
Why?
|
| Geographic Information Systems | 1 | 2018 | 28 | 0.140 |
Why?
|
| Geographic Mapping | 1 | 2018 | 14 | 0.140 |
Why?
|
| Illinois | 1 | 2020 | 520 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 887 | 0.140 |
Why?
|
| Crime | 1 | 2018 | 38 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2018 | 174 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2024 | 822 | 0.140 |
Why?
|
| Risk-Taking | 1 | 2019 | 158 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2020 | 482 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 179 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2018 | 364 | 0.130 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 18 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2026 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2020 | 295 | 0.120 |
Why?
|
| Symptom Assessment | 1 | 2016 | 71 | 0.120 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2016 | 28 | 0.120 |
Why?
|
| Penicillins | 1 | 2016 | 24 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1932 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 39 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2802 | 0.120 |
Why?
|
| Medicaid | 1 | 2018 | 258 | 0.110 |
Why?
|
| Seasons | 1 | 2016 | 240 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2018 | 328 | 0.110 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 25 | 0.110 |
Why?
|
| France | 2 | 2025 | 53 | 0.110 |
Why?
|
| Nasopharynx | 1 | 2015 | 51 | 0.110 |
Why?
|
| Bacteriuria | 1 | 2014 | 10 | 0.110 |
Why?
|
| Pneumonia | 1 | 2016 | 193 | 0.110 |
Why?
|
| Viruses | 1 | 2015 | 64 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 251 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2014 | 82 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1922 | 0.100 |
Why?
|
| Infant | 2 | 2019 | 3220 | 0.100 |
Why?
|
| Obesity | 1 | 2020 | 1018 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2019 | 3829 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 894 | 0.090 |
Why?
|
| Child | 3 | 2020 | 7355 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 7063 | 0.090 |
Why?
|
| Trust | 2 | 2023 | 97 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 876 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 889 | 0.080 |
Why?
|
| Social Stigma | 2 | 2022 | 86 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1917 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2014 | 454 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 185 | 0.080 |
Why?
|
| Bacteria | 1 | 2014 | 509 | 0.080 |
Why?
|
| Seroepidemiologic Studies | 2 | 2019 | 56 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1999 | 183 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2020 | 9103 | 0.060 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2017 | 13 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 1321 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2016 | 295 | 0.060 |
Why?
|
| Global Health | 2 | 2017 | 208 | 0.060 |
Why?
|
| Urinary Tract Infections | 2 | 2014 | 85 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 35 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 30 | 0.040 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 452 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 104 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 26 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2020 | 30 | 0.040 |
Why?
|
| Patient Participation | 1 | 2022 | 229 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 190 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 624 | 0.040 |
Why?
|
| Bone Diseases | 1 | 1999 | 52 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 1999 | 10 | 0.040 |
Why?
|
| Transgender Persons | 1 | 2021 | 113 | 0.040 |
Why?
|
| Synovial Membrane | 1 | 1999 | 31 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 157 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 657 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 712 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 179 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 284 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 1191 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1999 | 3476 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2016 | 125 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 25 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2016 | 60 | 0.030 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 65 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 126 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 89 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1105 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1994 | 14 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 31 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2014 | 24 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1702 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1994 | 139 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2479 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 893 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1994 | 409 | 0.020 |
Why?
|
| Prognosis | 2 | 2017 | 3912 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 62 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 150 | 0.020 |
Why?
|
| Contrast Media | 1 | 1994 | 988 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 1366 | 0.020 |
Why?
|
| Gadolinium DTPA | 2 | 1999 | 233 | 0.010 |
Why?
|
| Bone Cysts | 1 | 1999 | 8 | 0.010 |
Why?
|
| Synovitis | 1 | 1999 | 14 | 0.010 |
Why?
|
| Finger Joint | 1 | 1999 | 13 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 790 | 0.010 |
Why?
|
| Laminectomy | 1 | 1994 | 62 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1994 | 358 | 0.010 |
Why?
|